Perspective from Rishi P. Singh, MD Opthea has discontinued development of sozinibercept in wet age-related macular degeneration, according to a press release. After the March 24 release of ...

(RTTNews) - Opthea Limited (OPT, OPT.AX) announced its decision to discontinue the development of sozinibercept for wet age-related macular degeneration or wet AMD. This follows the negative ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

Opthia could owe its investors more than $1bn following the results of its Phase III Combination OPT-302 with Aflibercept Study (COAST) trial (NCT04757636), which evaluated its sozinibercept ...

Opthea is scrapping development of lead product candidate sozinibercept in wet age-related macular degeneration, or wet AMD, following the failure of another late-stage study. Opthea on Monday ...

The firm cites the company announcing that its Phase 3 COAST trial of sozinibercept in combination with Eylea in wet age-related macular degeneration failed to meet its primary endpoint ...

The studies of sozinibercept 2 mg (Opthea), also known as OPT-302, failed to meet their primary endpoint of improvement in best corrected visual acuity (BCVA) after a year of treatment when ...

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52Opthea and DFA ...

After announcing that lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD), Opthea has now decided to close the Coast trial as well as ...

Opthea Ltd. is considering its options after lead candidate sozinibercept (OPT-302) failed the phase III Coast trial in wet age-related macular degeneration (AMD). The global Coast phase III trial ...